Andrew W. Harrell

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Melanie Z. Sakatis, Melinda J. Reese, Andrew W. Harrell et al. · Chemical Research in Toxicology · 2012 · 120 citations

System Pharmacology, Vitro Bioactivation Data, Pharmacodynamic Modeling +21

Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.

S. E. Clarke, Andrew W. Harrell, R J Chenery · Drug Metabolism and Disposition · 1995 · 103 citations

Artesunate: developmental toxicity and toxicokinetics in monkeys

Robert L. Clark, Akihiro Arima, Norbert Makori et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 2008 · 69 citations

Live Embryos, Developmental Biology, Gestation Days +15

Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans

Andrew W. Harrell, Sarah Siederer, Jo Bal et al. · Drug Metabolism and Disposition · 2012 · 53 citations

Interrogating the relationship between rat in vivo tissue distribution and drug property data for >200 structurally unrelated molecules

Andrew W. Harrell, Caroline Sychterz, May Y. K. Ho et al. · Pharmacology Research & Perspectives · 2015 · 32 citations · Full text